Liver Cancer

In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.

“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.

Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.

Over the last 30 years, cases of childhood liver cancer have increased in the United States, Australia and a Canadian province.

A roundup of liver cancer news and updates that occurred in 2020 patients with cancer may have missed.

A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.

Results of this trial led to an accelerated FDA approval of Opdivo (nivolumab) and Yervoy (ipilimumab) in March to treat this specific patient population.

Overall survival was better with hepatic arterial infusion chemotherapy compared with transarterial chemoembolization, according to phase 3 study findings.

Younger and female patients with a variety of cancer types tend to have strong immune systems that naturally fight an array of cancer cells. The tumor cells the immune system doesn’t destroy are the most evasive, both to the immune system and medications that boost its activity, and this makes checkpoint inhibitor immunotherapy less effective in this population.

At a median follow-up of 10 months, all patients who received Tafinlar plus Mekinist achieved an overall response rate of 51%.

Could paradigm shifts in cancer research help find a cure for cholangiocarcinoma? Experts discuss.

After lifesaving medicine became available to treat hepatitis C virus, a risk factor for liver cancer, racial inequities in the death rate from the malignancy began a steady upward climb.

The results of an ongoing study designed to reveal genetic characteristics linked with the development of cholangiocarcinoma could pave the way for more accurate prognoses, as well as new treatments.

A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives.

After losing the sister she raised to an aggressive type of liver cancer, one woman has devoted herself to stamping out the disease.

U.S. Supreme Court Justice Ruth Bader Ginsburg, 87, has announced that she is currently undergoing chemotherapy for a cancer recurrence.

When it comes to hepatocellular carcinoma (HCC), doctors have a handful of treatment options at their disposal. But how do they decide what’s best?

A caregiver sheds light on the trials and tribulations of his wife's cancer journey and describes his awe in watching his wife's strength.

The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.

In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.

Nonalcoholic fatty liver disease can lead to cancer. Patients can reverse the damage through diet and exercise, but how can they know if they have the common condition?

The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.

A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.

The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Here’s what you need to know.

The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.